AMGEN INC
Amgen discovers, develops, manufactures and delivers medicines for human diseases. It operates in one segment, human therapeutics, and has a presence in approximately 100 countries worldwide. Its marketed products include medicines for conditions such as osteoporosis, cancer, cardiovascular disease, asthma and inflammatory disorders, including Prolia, Repatha, BLINCYTO, TEZSPIRE and Otezla. Amgen also develops product candidates through clinical research. Amgen sells medicines to healthcare providers and pharmaceutical wholesale distributors, using its own affiliates, sales and marketing teams, and third-party partners in different markets. In the United States, substantially all sales are to pharmaceutical wholesale distributors; in other countries, sales are principally to healthcare providers or distributors. The company markets products to providers including physicians, dialysis centers, hospitals and pharmacies, and also uses direct-to-patient channels for certain products. Amgen is headquartered in Thousand Oaks, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMGN in the last 30 days.
See all $AMGN insider activity →Novartis reported seven new tumor cases in children treated with its gene therapy Zolgensma, bringing the total to nine since 2019. The company disclosed the cases in a regulatory filing, according to STAT.
Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.
Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, driven by sales growth in Repatha, UPLIZNA, and IMDELLTRA. GAAP EPS rose 19% to $7.08. Full-year revenue guidance is $38.9B-$39.7B. Free cash flow was $3.7B, with $13.2B in cash and $54B in debt.
Over the past 7 days, AlphAI's AI scored 86 news stories mentioning AMGN (AMGEN INC). Coverage has skewed bullish: 61 bullish, 13 neutral, and 12 bearish.
Recent AMGN coverage spans earnings, financial news and regulation.
Novartis reported seven new tumor cases in children treated with its gene therapy Zolgensma, bringing the total to nine since 2019. The company disclosed the cases in a regulatory filing, according to STAT.
Analyst downgrade to Hold may temper the recent rally despite a higher price target.
Earnings beat and raised guidance suggest upside potential.
Regulatory approval maintains product's market status and may support short‑term price stability.
ETF buying may create modest short‑term buying pressure on AMGN.
AlphAI scores every news story that mentions AMGN with an AI model for sentiment and relevance, and aggregates insider trades from AMGEN INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Novartis reported seven new tumor cases in children treated with its gene therapy Zolgensma, bringing the total to nine since 2019. The company disclosed the cases in a regulatory filing, according to STAT.
Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.
Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, driven by sales growth in Repatha, UPLIZNA, and IMDELLTRA. GAAP EPS rose 19% to $7.08. Full-year revenue guidance is $38.9B-$39.7B. Free cash flow was $3.7B, with $13.2B in cash and $54B in debt.
The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.
Amgen (AMGN) saw $79.8M net inflows from ETFs on Wednesday, extending a four-day buying streak. Top buyers included DIA ($49.7M), XLV ($10.7M), and IBB ($8.4M). AMGN's market cap is $248.8B, with YTD gains of 43.5%. Revenue grew 8.1% YoY to $38.98B, with a 24.1% net margin. The stock trades at a P/E of 26.7.
Amgen (AMGN) reported Q3 earnings of $6.45 per share, beating estimates by 12%, with revenue of $10.4B, up 9% YoY. The company's stock has gained 72% since late 2024, driven by strong commercial performance and a robust pipeline. Analysts have mixed views on its valuation, with a forward P/E of 19.9x. Amgen has raised its dividend for 16 consecutive years, yielding 2.2%.
Amgen reported Q3 revenue of $10.4B, up 8%, with key growth drivers rising 27%. The company raised 2026 revenue and EPS guidance to $38.9B-$39.7B and $22.90-$23.70, respectively. Positive late-stage trial results and strong cash flow were highlighted, though TEPEZZA sales declined 6% and higher expenses are expected in Q4.
Leerink Partners kept Amgen's rating at Market Perform but increased its price target to $464 from $395, a 17.5% rise. This aligns with Amgen's recent close of $460.28. Recent analyst targets for Amgen range from $435 to $530.
Amgen (AMGN) shares rose 65.7% over the past year, trading at 26.5x adjusted earnings. Analysts expect FY2026 and FY2027 profits of $12.5B and $13.2B, with net margins of 32.0% and 32.6%, respectively. Amgen's revenue grew 8.2% year-over-year, exceeding the 4.1% forecasted growth. Management raised FY2026 revenue guidance to $39.3B. Investors are betting on profit growth outpacing sales, but rising R&D costs could pose a risk.
Guggenheim kept its Neutral rating on Amgen but raised its price target to $435 from $378, suggesting a 9.1% downside from the Nov 4 close. Recent analyst targets for Amgen range from $425 to $530.
